Trust Point Inc. Makes New Investment in Charles River Laboratories International, Inc. (NYSE:CRL)

Trust Point Inc. bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,045 shares of the medical research company’s stock, valued at approximately $378,000.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP raised its position in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares in the last quarter. State Street Corp raised its position in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after buying an additional 509,163 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Charles River Laboratories International by 6.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 515,222 shares of the medical research company’s stock worth $101,483,000 after buying an additional 32,311 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 1.6 %

Shares of NYSE:CRL opened at $165.70 on Thursday. The stock’s 50-day moving average price is $181.99 and its 200-day moving average price is $194.26. Charles River Laboratories International, Inc. has a 12-month low of $159.65 and a 12-month high of $275.00. The stock has a market capitalization of $8.47 billion, a P/E ratio of 20.74, a price-to-earnings-growth ratio of 6.25 and a beta of 1.37. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $2.72 earnings per share. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.17 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CRL. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Morgan Stanley reduced their target price on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Evercore ISI increased their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. UBS Group reissued a “neutral” rating and issued a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research note on Monday, November 18th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).